Emasenyie A. Isikwei

Family Medicine
1475 W 49th Pl
Hialeah, FL 33012

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Contemporary Mortality and Comparative Outcomes of Nephrectomy Versus Non-nephrectomy Management in Emphysematous Pyelonephritis: A Systematic Review and Meta-Analysis.

Contemporary Mortality and Comparative Outcomes of Nephrectomy Versus Non-nephrectomy Management in Emphysematous Pyelonephritis: A Systematic Review and Meta-Analysis.

Journal: Cureus
Published: April 02, 2026

Maternal and Neonatal Outcomes Associated With Cesarean Versus Vaginal Delivery in the United States: A Population-Based Retrospective Cross-Sectional Analysis of CDC Natality Public Use Data (2017-2020).

Maternal and Neonatal Outcomes Associated With Cesarean Versus Vaginal Delivery in the United States: A Population-Based Retrospective Cross-Sectional Analysis of CDC Natality Public Use Data (2017-2020).

Journal: Cureus
Published: March 12, 2026

Early Versus Delayed Norepinephrine Initiation in Septic Shock: A Systematic Review and Meta-Analysis of Randomized and Observational Studies.

Early Versus Delayed Norepinephrine Initiation in Septic Shock: A Systematic Review and Meta-Analysis of Randomized and Observational Studies.

Journal: Cureus
Published: December 07, 2025

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 16, 2024

A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.

A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.

Journal: Pediatric blood & cancer
Published: August 02, 2023

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

Journal: Pediatric blood & cancer
Published: April 20, 2023

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 11, 2022

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 18, 2022
Showing 1-8 of 8

Last Updated: 09/26/2026